Nottingham, UK – May 10, 2021 — Calyx, the eClinical solutions and services provider most relied on for solving complex data challenges in clinical research, today announced that Catalyst Clinical Research will enter into a partnership with Calyx to leverage Calyx’s Medical Imaging solution for their customers’ oncology trials.
A leading provider of clinical research services, Catalyst Clinical Research’s full-service, niche oncology CRO solution is focused on next-generation cancer therapies. Catalyst Oncology offers skilled management of immuno-oncology and targeted therapies, as well as expert oversight of complex study designs to deliver customized clinical research solutions exclusively for the biotech market.
“We see a lot of synergies between Calyx’s expertise in medical imaging, particularly in early-phase oncology development, and Catalyst Oncology’s clinical development services for the advancement of new cancer treatments,” said Andrew Zupnick, PhD, Vice President of Oncology Drug Development at Catalyst. “We’re pleased to form a relationship through their CRO partnership program and look forward to working together as we help our customers bring novel therapies to cancer patients in need.”
The ACTIVATE Solutions for CRO Partners program is designed to provide close alignment between Calyx and its CRO partners. By participating in the ACTIVATE CRO program, Catalyst can better meet the imaging needs of their clients and help accelerate oncology trial execution and data collection, ultimately delivering more customer value.
“Catalyst is at the forefront in delivering customized services that meet the evolving needs and unexpected changes inherent in oncology clinical development,” said John Blakeley, Chief Commercial Officer at Calyx. “We’re delighted to welcome them to our partnership network and to support their knowledgeable, experienced team with a proven imaging solution as they execute complex oncology trials for their biotech clients.”
